Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
CARLSBAD, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has expanded its commercial team in North America with the addition of Michael Harkins as Senior Vice President of Sales.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
"Mike brings an impressive background of commercial leadership to GenMark, and I am very pleased to welcome him to our company. With his breadth of experience building and leading sales teams, I am confident that Mike will help drive our commercial success in North America, as we continue to invest in sales force expansion and commercial excellence," said Hany Massarany, President and Chief Executive Officer.
Prior to joining GenMark, Harkins held several senior commercial leadership roles at Thermo Fisher Scientific, where he led sales teams for nearly 15 years, most recently serving as Vice President, Global Commercial Sales for the Bioproduction Division.
Michael Gleeson, who has successfully led the company's U.S. sales force for almost nine years, is now focused on his new role as Senior Vice President of Corporate and Strategic Accounts. In this role, Gleeson will establish and lead a team of commercial executives to continue building long-term partnerships across the Company's most strategic customer segments, which include Integrated Delivery Networks, Group Purchasing Organizations, and other major accounts.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
"Building a world class commercial organization is a key priority for our company and I'm confident that adding Mike Harkins to our team and enabling Mike Gleeson to focus on our most strategic accounts will help us reach that goal," concluded Massarany.
About GenMark Diagnostics
GenMark Diagnostics (NASDAQ:GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® and ePlex® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark's ePlex: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visit www.genmarkdx.com.
Forward Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding the company's future commercial success and expansion of its commercial organization, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, our ability to successfully commercialize e our ePlex system and its related test menu in a timely manner, including our BCID Panels, constraints or inefficiencies caused by unanticipated acceleration and deceleration of customer demand, our ability to successfully expand sales of our product offerings outside the United States, and third-party payor reimbursement to our customers, as well as other risks and uncertainties described under the "Risk Factors" in our public filings with the Securities and Exchange Commission. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.
Investor Relations Contact
Leigh Salvo
(415) 937-5404
ir@genmarkdx.com
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.